Benjamin P. Levy, MD, discusses the evolution of molecular drivers in non–small cell lung cancer over the last few years and which testing should be included in patients.
Benjamin P. Levy, MD, clinical director of medical oncology and associate professor of oncology at Johns Hopkins Sidney Kimmel Cancer Center in Sibley Memorial Hospital, Washington, DC, discusses the evolution of molecular drivers in nonsmall cell lung cancer (NSCLC) over the last few years and which testing should be included in patients with NSCLC.
Levy says research has come a long way in terms of the molecular driver identification in NSCLC. Initially, it started with testing forEGFRandALKin patients with advanced adenocarcinoma of the lung, but now there are a number of mutations that we can test for, including RET, ROS1, BRAF, HER2, METexon 14 skipping, NTRK,andKRAS.If these mutations are identified, patients can be treated with a targeted therapy that has been approved by the FDA or is under the umbrella of a clinical trial.
The list continues to grow in terms of actionable mutations that should be tested for, Levy says. He says this is a call for comprehensive genomic profiling for lung cancer. More testing should be done outside of sequentialEGFR, ALK, ROS1,andBRAF. Larger panels can be used to identify all of the mutations necessary at this time to improve outcomes for patients with NSCLC harboring 1 of these mutations.
For more from Levy's interview withTargeted Oncology:
https://www.targetedonc.com/conference/nylung-2019/expert-reviews-evolving-treatment-standards-for-nondriver-and-molecularly-driven-nsclc
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More